Radiation Oncology Journal

  • 제35권3호
  • /
  • Pages.249-256
  • /
  • 2017
  • /
  • 2234-1900(pISSN)
  • /
  • 2234-3156(eISSN)
대한방사선종양학회 (The Korean Society for Radiation Oncology)
권호 표지
DOI QR코드

DOI QR Code

Treatment outcome and risk analysis for cataract after radiotherapy of localized ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphoma

  • Park, Hee Hyun (Department of Radiation Oncology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Lee, Sea-Won (Department of Radiation Oncology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Sung, Soo Yoon (Department of Radiation Oncology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Choi, Byung Ock (Department of Radiation Oncology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea)
  • 투고 : 2017.07.18
  • 심사 : 2017.09.18
  • 발행 : 2017.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: We retrospectively reviewed the results of radiotherapy for localized ocular adnexal MALT lymphoma (OAML) to investigate the risk factors of cataract. Methods: Sixty-seven patients with stage IE OAML treated with radiotherapy at Seoul St. Mary's Hospital from 2001 to 2016 were included. Median treatment dose was 30 Gy. Lens protection was done in 52 (76%) patients. Radiation therapy (RT) extent was as follows: superficial (82.1%), tumor mass (4.5%), and entire orbital socket (13.4%). The risk factors for symptomatic cataract were analyzed using the Cox proportional hazard model. Results: Median follow-up time was 50.9 months (range, 1.9 to 149.4 months). All patients were alive at the time of analysis. There were 7 recurrences and there was no local recurrence. Median time to recurrence was 40.4 months. There were 14 cases of symptomatic cataract. Dose >30 Gy had hazard ratio of 3.47 for cataract (p = 0.026). Omitting lens protection showed hazard ratio of 4.10 (p = 0.008). Conclusions: RT achieves excellent local control of ocular MALT lymphoma. Consideration of RT-related factors such as lens protection and radiation dose at the stage of RT planning may reduce the risk of RT-induced cataract after radiotherapy.

키워드

참고문헌

  1. Kim JM, Ko YH, Lee SS, et al. WHO classification of malignant lymphomas in Korea: report of the third nationwide study. Korean J Pathol 2011;45:254-60. https://doi.org/10.4132/KoreanJPathol.2011.45.3.254
  2. White WL, Ferry JA, Harris NL, Grove AS Jr. Ocular adnexal lymphoma: a clinicopathologic study with identification of lymphomas of mucosa-associated lymphoid tissue type. Ophthalmology 1995;102:1994-2006. https://doi.org/10.1016/S0161-6420(95)30764-6
  3. Goda JS, Gospodarowicz M, Pintilie M, et al. Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. Cancer 2010;116:3815-24. https://doi.org/10.1002/cncr.25226
  4. Ferrufino-Ponce ZK, Henderson BA, Radiotherapy and cataract formation. Semin Ophthalmol 2006;21:171-80. https://doi.org/10.1080/08820530500351728
  5. Swerdlow S, Campo E, Harris N, et al. WHO classification of tumors of hematopoietic and lymphoid tissues. 4th ed. Geneva: World Health Organization; 2008.
  6. Hata M, Omura M, Koike I, et al. Treatment effects and sequelae of radiation therapy for orbital mucosa-associated lymphoid tissue lymphoma. Int J Radiat Oncol Biol Phys 2011;81:1387-93. https://doi.org/10.1016/j.ijrobp.2010.07.1992
  7. US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 4.0. Washington, DC: National Institutes of Health, National Cancer Institute; 2009.
  8. Hall EJ, Giaccia AJ. Radiobiology for the radiologist. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2012.
  9. Ejima Y, Sasaki R, Okamoto Y, et al. Ocular adnexal mucosaassociated lymphoid tissue lymphoma treated with radiotherapy. Radiother Oncol 2006;78:6-9. https://doi.org/10.1016/j.radonc.2005.11.005
  10. Platt S, Al Zahrani Y, Singh N, Hill B, Cherian S, Singh AD. Extranodal marginal zone lymphoma of ocular adnexa: outcomes following radiation therapy. Ocul Oncol Pathol 2017;3:181-7. https://doi.org/10.1159/000453615
  11. Harada K, Murakami N, Kitaguchi M, et al. Localized ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiation therapy: a long-term outcome in 86 patients with 104 treated eyes. Int J Radiat Oncol Biol Phys 2014;88:650-4. https://doi.org/10.1016/j.ijrobp.2013.11.235
  12. Goda JS, Le LW, Lapperriere NJ, et al. Localized orbital mucosaassociated lymphoma tissue lymphoma managed with primary radiation therapy: efficacy and toxicity. Int J Radiat Oncol Biol Phys 2011;81:e659-66. https://doi.org/10.1016/j.ijrobp.2011.03.050
  13. Uno T, Isobe K, Shikama N, et al. Radiotherapy for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue originating in the ocular adnexa. Cancer 2003;98:865-71. https://doi.org/10.1002/cncr.11539
  14. Hashimoto N, Sasaki R, Nishimura H, et al. Long-term outcome and patterns of failure in primary ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiotherapy. Int J Radiat Oncol Biol Phys 2012;82:1509-14. https://doi.org/10.1016/j.ijrobp.2011.04.052
  15. Nam H, Ahn YC, Kim YD, Ko Y, Kim WS. Prognostic significance of anatomic subsites: results of radiation therapy for 66 patients with localized orbital marginal zone B cell lymphoma. Radiother Oncol 2009;90:236-41. https://doi.org/10.1016/j.radonc.2008.09.011
  16. Suh CO, Shim SJ, Lee SW, Yang WI, Lee SY, Hahn JS. Orbital marginal zone B-cell lymphoma of MALT: radiotherapy results and clinical behavior. Int J Radiat Oncol Biol Phys 2006;65:228-33. https://doi.org/10.1016/j.ijrobp.2005.11.035
  17. Monzen Y, Hasebe H. Radiotherapy for localized orbital mucosa-associated lymphoid tissue lymphoma. Ophthalmologica 2007;221:233-7. https://doi.org/10.1159/000101924
  18. Lee JL, Kim MK, Lee KH, et al. Extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue-type of the orbit and ocular adnexa. Ann Hematol 2005;84:13-8. https://doi.org/10.1007/s00277-004-0914-3
  19. Tran KH, Campbell BA, Fua T, et al. Efficacy of low dose radiotherapy for primary orbital marginal zone lymphoma. Leuk Lymphoma 2013;54:491-6. https://doi.org/10.3109/10428194.2012.717279
  20. Ohga S, Nakamura K, Shioyama Y, et al. Radiotherapy for early-stage primary ocular adnexal mucosa-associated lymphoid tissue lymphoma. Anticancer Res 2013;33:5575-8.
  21. Leske MC, Chylack LT Jr, Wu SY. The lens opacities casecontrol study: risk factors for cataract. Arch Ophthalmol 1991;109:244-51. https://doi.org/10.1001/archopht.1991.01080020090051
  22. Javitt JC, Wang F, West SK. Blindness due to cataract: epidemiology and prevention. Annu Rev Public Health 1996;17:159-77. https://doi.org/10.1146/annurev.pu.17.050196.001111
  23. Yahalom J, Illidge T, Specht L, et al. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2015;92:11-31. https://doi.org/10.1016/j.ijrobp.2015.01.009
  24. Fasola CE, Jones JC, Huang DD, Le QT, Hoppe RT, Donaldson SS. Low-dose radiation therapy (2 Gy $\times$ 2) in the treatment of orbital lymphoma. Int J Radiat Oncol Biol Phys 2013;86:930-5. https://doi.org/10.1016/j.ijrobp.2013.04.035
  25. Eng T, Ha CS. Image-guided radiation therapy in lymphoma management. Radiat Oncol J 2015;33:161-71. https://doi.org/10.3857/roj.2015.33.3.161

피인용 문헌

  1. Treatment-associated outcomes of patients with primary ocular adnexal MALT lymphoma after accurate diagnosis vol.24, pp.12, 2019, https://doi.org/10.1007/s10147-019-01481-3
  2. Patterns of care for orbital marginal zone B‐cell lymphoma of mucosa‐associated lymphoid tissue in Korea throughout 2016: Results from a multicenter cross‐sectional cohort study ( vol.15, pp.6, 2017, https://doi.org/10.1111/ajco.13221
  3. Ocular adnexal marginal zone B-cell lymphoma: the low-dose dilemma vol.104, pp.2, 2017, https://doi.org/10.1136/bjophthalmol-2019-314861